Ankylosing spondylitis: Introductory comments on its diagnosis and treatment

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 3, 2002, Pages

  Khan, M A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DYSPEPSIA; EARLY DIAGNOSIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; NAUSEA; ONSET AGE; PATHOGENESIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; TH1 CELL;

EID: 17644447542     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.suppl_3.iii3     Document Type: Conference Paper

References (69)

1. Khan MA. Ankylosing spondylitis: Clinical features. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M, eds. Rheumatology. 3rd Ed. London, Mosby-Wolfe. In press.
2. Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002;18:896-907.
3. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988;15:1109-14.
4. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Evaluation of early diagnostic criteria for ankylosing spondylitis in a 10 year follow-up. Z Rheumatol 1990;49:82-7.
5. Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 2000;12:239-47.
6. Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural course of ankylosing spondylitis. Arthritis Rheum 1983;26:186-90.
7. Burgos-Vargas R, Petty RE. Juvenile ankylosing spondylitis. Rheum Dis Clin North Am 1992;18:123-42.
8. Olivieri I, Salvarani C, Cantini F, Ciancio G, Padula A. Ankylosing spondylitis and undifferentiated spondyloarthropathies: A clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol 2001;13:280-4.
9. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
10. Boonen A, van der Heijde D, Landewe R, Rutten M, Spoorenberg A, Schouten H, et al. Work status and productivity costs due to ankylosing spondylitis: Comparison among three European countries. Ann Rheum Dis 2002;61:429-37.
11. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
12. Zeidler H, Mau W, Khan MA. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am 1992;18:187-202.
13. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-30.
14. Amor B, Dougados M, Listrat V, Menkes CJ, Roux H, Benhamou C, et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995;62:10-15.
15. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995;21:117-28.
16. Bakker C, Boers M, van der Linden S. Measures to assess ankylosing spondylitis: Taxonomy, review, and recommendation. J Rheumatol 1993;20:1724-30.
17. Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the long term outcome of spondyloarthropathies. J Rheumatol 1994;21:1789-90.
18. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997;24:2225-9.
19. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
20. Dougados M, Revel M, Khan MA. Spondyloarthropathy treatment: Progress in medical therapy. Baillieres Clin Rheumatol 1998;12:717-36.
21. Palferman TG, Weblely M. A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm 1991;11:23-9.
22. Calin A. Clinical use of tolmetin sodium in patients with ankylosing spondylitis: A review. J Clin Rheumatol 1983;23:301-8.
23. Schwarzer AC, Cohen M, Arnold MH, Kelly D, McNaught P, Brooks PM. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Curr Med Res Opin 1990;11:648-53.
24. Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H, et al. Evaluation des critères de spondylarthropathies d'Amor et de l'European Spondylarthropathy Study Group (ESSG). Une etude transversale de 2229 patients. Ann Med Interne (Paris) 1991;142:85-9.
25. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983;74:820-8.
26. Paulus HE. FDA arthritis advisory committee: Serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, etc. Arthritis Rheum 1988;31:1450-1.
27. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study. A randomized controlled trial. JAMA 2000;248:1247-55.
28. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-8.
29. Hochberg M, ed. Coxibs: Evolution of a revolutionary class. Evolving class and issues surrounding COX-2 inhibitors. Cleveland Clin J Med 2002;69(suppl 1):si-1-84.
30. Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
31. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Zeidler H, et al. Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
32. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
33. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efficacy of methotrexate in the treatment of ankylosing spondylitis: A three-year open study. Clin Rheumatol 2000;19:114-17.
34. Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9.
35. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000;29:160-2.
36. Roychaudhry B, Bintley-Bagot S, Hunt J, Tunn EJ. Methotrexate in severe ankylosing spondylitis: A randomized placebo controlled, double-blind observer study [abstract]. Rheumatology 2001;40(suppl 1):43.
37. Williamson L, Illingworth H, Smith D, Mowat A. Oral quinine in ankylosing spondylitis: A randomized placebo controlled double blind crossover trial. J Rheumatol 2000;27:2054-5.
38. Braun J, Bollow M, Seyrekbasan F, Haberle HJ, Eggens U, Mertz A, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: Clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 1996;23:659-64.
39. Gunaydin I, Pereira PL, Daikeler T, Mohren M, Trubenbach J, Schick F, et al. Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: A pilot study. J Rheumatol 2000;27:424-8.
40. Granfors K, Märker-Hermann E, De Keyser P, Khan MA, Veys EM, Yu DT. The cutting edge of spondyloarthropathy research in the millennium. Arthritis Rheum 2002;46:606-13.
41. Khan MA, Ball EJ. Ankylosing spondylitis and genetic aspects. Baillieres Best Pract Res Clin Rheumatol (in press).
42. Laval SH, Timms A, Edwards S, Bradbury L, Brophy S Milicic A, et al. Whole-genome screening in ankylosing spondylitis: Evidence of non-MHC geneticsusceptibility loci. Am J Hum Genet 2001;68:916-26.
43. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;14:397-440.
44. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
45. Mielants H, Veys EM, Cuvelier C, De Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 1996;10:147-64.
46. Kavanaugh AF. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614.
47. Beckham JC, Caldwell DS, Peterson BL, Pippen AM, Currie MS, Keefe FJ, et al. Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neoplerin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61.
48. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
49. Hanauer SB, Lichtenstein GR, Columbel J-F, Mayer L, Schreiber S, Rachmilewicz D. Maintenance infliximab (Remicade) is safe, effective and steroid sparing in Crohn's disease: Preliminary results from the ACCENT I trial [abstract]. Gastroenterology 2001;120:A21.
50. Miani R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
51. Moreland LW, Schiff MWH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
52. Lipsky P, St Clair W, Furst D, Breedveld F, Smolen J, Kalden JR, et al. 54-Week clinical and radiographic results from the ATTRACT trial: A phase III study of infliximab (Remicade®) in patients with active RA despite methotrexate [abstract]. Arthritis Rheum 1999;42:S401.
53. Finck B, Martin R, Fleischmann R, Moreland L, Schiff M, Bathon J. A phase III trial of etanercept vs. methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial) [abstract]. Arthritis Rheum 1999;42:S177.
54. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
55. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518-23.
56. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52.
57. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
58. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
59. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001;60:36-42.
60. Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001;60:750-5.
61. Van Damme N, De Vos M, Baeten D, Demetter P, Mielants H, Verbruggen G, et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 2001;60:495-9.
62. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondyloarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-95.
63. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicentre trial. Lancet 2002;359:1187-93.
64. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
65. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
66. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000;356:385-90.
67. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
68. Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999;42:580-1.
69. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClerq S, Chiu P, Yan A, et al. A six-month randomized controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of non-steroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.